文献速递免疫规划卫生政策与健康促进

评估八国COVID-19加强针疫苗的成本效果模型:方法与数据输入综述

Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs.
PubMed 文献 · Vaccine · 2025-02-15

针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)从大流行转向地方性流行,对英国、西班牙、德国、法国、意大利、美国、加拿大和澳大利亚的9项COVID-19疫苗成本效果研究进行针对性文献综述,评估加强针接种并主要考虑mRNA疫苗,发现疫苗具健康获益且具成本效果或成本节约,老年和高危人群获益更明显,结果对发病率、传播性、疫苗效果、保护衰减和住院成本最敏感。

要点

  • 9项成本效果研究显示COVID-19疫苗提供健康获益且具成本效果或成本节约。
  • 基于更高的住院和死亡 rates,老年和高危人群获益更明显。
  • 结果对COVID-19发病率、传播性、疫苗效果、保护衰减和住院成本最敏感。

核心结论

  • 成本效果研究显示COVID-19疫苗提供健康获益且具成本效果或成本节约,老年和高危人群获益更明显。

研究设计与样本

  • 针对性文献综述,纳入来自英国、西班牙、德国、法国、意大利、美国、加拿大和澳大利亚的9项成本效果研究。

主要发现

  • 9项成本效果研究评估加强针接种,主要考虑mRNA疫苗。
  • 成本效果研究显示COVID-19疫苗提供健康获益且具成本效果或成本节约。
  • 基于更高的COVID-19住院和死亡 rates,老年和高危人群获益更明显。
  • 成本效果结果对COVID-19发病率、SARS-CoV-2传播性、疫苗效果、疫苗保护衰减/持续时间和住院成本的估计最敏感。
  • 大多数数据输入来源于真实世界证据(RWE)。

关键数值与推荐

  • 未纳入传播建模、生产力损失和长COVID影响等参数可能低估COVID-19疫苗价值。
  • 随着SARS-CoV-2演变和COVID-19疫苗更新,需要持续生成真实世界证据以持续展示COVID-19疫苗的成本效果。

局限性

  • 未纳入传播建模、生产力损失和长COVID影响等参数可能低估COVID-19疫苗价值。
  • 随着SARS-CoV-2演变和COVID-19疫苗更新,需要持续生成真实世界证据以持续展示COVID-19疫苗的成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronavirus disease 2019 (COVID-19) continues to cause serious health consequences globally. Policy makers now assess cost effectiveness (CE) when evaluating COVID-19 vaccines. A targeted literature review was performed to examine recent CE evidence for COVID-19 vaccines, as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transitions from pandemic to endemic, to identify best practices. Data were from large EU countries (UK, Spain, Germany, France, and Italy), US, Canada, and Australia. Nine CE studies met the inclusion criteria. Studies evaluated booster vaccination, and mainly considered mRNA vaccines. CE studies reported that COVID-19 vaccines provided health benefits and were cost-effective or showed cost-savings. Benefits were more pronounced in older and high-risk populations based on higher rates of COVID-19 hospitalization and death. CE findings were most sensitive to estimates of incidence of COVID-19, SARS-CoV-2 transmissibility, vaccine effectiveness, waning/duration of vaccine protection, and hospitalization costs. Most data inputs were sourced from real-world evidence (RWE). Lack of inclusion of some parameters, such as transmission modeling, productivity losses, and the impact of long COVID may undervalue COVID-19 vaccines. As SARS-CoV-2 evolves and COVID-19 vaccines are updated, continuous generation of RWE is needed to demonstrate the CE of COVID-19 vaccines in an ongoing manner.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Smith DS, Postma M, Fisman D, et al. Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs. Vaccine. 2025. PMID: 39956089. doi:10.1016/j.vaccine.2025.126879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。